Affordable Access

deepdyve-link
Publisher Website

Effect of oncometabolic surgery on gastric cancer: The remission of hypertension, type 2 diabetes mellitus, and beyond

Authors
  • Cheng, Yu-Xi
  • Peng, Dong
  • Tao, Wei
  • Zhang, Wei
Type
Published Article
Journal
World Journal of Gastrointestinal Oncology
Publisher
Baishideng Publishing Group Inc
Publication Date
Sep 15, 2021
Volume
13
Issue
9
Pages
1157–1163
Identifiers
DOI: 10.4251/wjgo.v13.i9.1157
PMID: 34616520
PMCID: PMC8465439
Source
PubMed Central
Keywords
Disciplines
  • Minireviews
License
Unknown

Abstract

This review summarizes the definition and surgical methods of oncometabolic surgery according to previous studies. Then, the authors discuss the beneficial effects observed after gastrectomy in gastric cancer (GC) patients with concurrent hypertension or type 2 diabetes mellitus (T2DM). The authors summarize the current studies analyzing the remission rate and the hypotheses of the mechanisms underlying these effects. The remission rate ranged from 42.5%-65.4% in T2DM patients and from 11.1%-57.6% among those with hypertension. Furthermore, the remission of T2DM could have an impact on overall survival rates as well. The mechanisms underlying the remission of hypertension and T2DM is unclear in current studies, but oncometabolic surgery is expected to be applied in clinical practice. In addition, the effect of oncometabolic surgery on other chronic metabolic comorbidities is expected to be proven in further studies. Therefore, the purpose of this review is to discuss the effects of oncometabolic surgery reported in current studies with a primary focus on the remission of hypertension and T2DM after gastrectomy in GC patients. The possibility of the remission of other metabolic comorbidities in GC patients who undergo oncometabolic surgery is also discussed.

Report this publication

Statistics

Seen <100 times